Merck Serono Expects M&A to Build China Sales

Merck Serono AG, the biopharma arm of German chemical and pharma giant Merck KGaA, plans to use M&A to grow its presence in China. Although the company will soon announce the construction of its own drug manufacturing facility, Merck Serono hopes to buy local companies involved in manufacturing or distribution, according to Howard Sui, chairman and president of Merck Serono China. Merck Serono wants to be vertically integrated in the PRC, and it plans to extend its distribution to China’s grassroots market. More details.... Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});